SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

Share Price is delayed by 15 minutes
Get Live Data
141.60    -24.20 (-14.60%)
Bid:
140.20
Ask:
144.80
Spread: 4.60 (3.281%)
Market Cap: £241.94m
MCB Live PriceLast checked at - London Stock Exchange

Intraday Mcbride Share Chart

Refinancing on improved terms

27 Jun 2017 07:00

RNS Number : 2177J
McBride PLC
27 June 2017
Β 

27 June 2017

Β 

McBride plc

Β 

Refinancing on improved terms

Β 

McBride plc ("the Group"), the leading European manufacturer and supplier of Co-manufactured and Private Label products for the Household and Personal Care market, today announces the refinancing of the Group in further support of the Group's Repair, Prepare, Grow strategy.

Β 

The Group has secured replacement banking facilities from a panel of international banks and using these increased facilities will repay its US Private Placement Notes ("USPP"). These actions will lower the cost of the Group's debt financing from the financial year starting on 1 July 2017 by approximately Β£2.0m per year.

Β 

Β 

Replacement Bank Facilities

Β 

The existing EUR 140m multi-currency revolving credit facility ("RCF") has beenΒ increased to a five year EUR 175m facility with a maturity of June 2022.

Β 

Features of the replacement facilitiesΒ include:

Β 

- a EUR 175m RCF of which approximately EUR 70m will be drawn, providing the Group with significant committed funding headroom

- a 5 bps reduction in both margin and non-utilisation fees

- the addition of further borrowing entities and currencies, increasing flexibility going forward

- a EUR 75m uncommitted accordion feature will provide additional facilities for potential future acquisitions in support of the Grow phase of our strategy

Β 

The bank facilities areΒ provided by a syndicate of HSBC, KBC, Bayern LB, BNP Paribas and Barclays.

Β 

US Private Placement Notes

Β 

The existing $50m 5.51%1 2020 USPP and $40m 5.38%1 2022 USPP will be repaid in full by drawing on the increased RCF.

Β 

Under the terms of the USPP arrangements, the Group will pay a 'make-whole' payment to existing USPP note-holders of approximately Β£11m2. At the same time the Group will close out the Euro/Dollar cross-currency interest rate swaps relating to the existing USPP notes which have a current mark-to-market net value of approximately Β£11m3 in favour of the Group.

Β 

Financing charges

Β 

Based on the current level of borrowings and interest swap rates, and taking into consideration the amortisation of initial fees, the Group's pro forma annual underlying finance charge will, over a full year, reduce by approximately Β£2m4 per annum. The Group's overall ongoing average cost of debt, after the repayment of the USPP, will reduce by approximately 310bps 4 to 150bps.

Β 

The 'make whole' payment to USPP note-holders will be treated for the Group's financial statements for the 12 months to 30 June 2017 as an exceptional finance charge. The total exceptional finance charge associated with this transaction will be approximately Β£13m comprising the make whole payment and additional USPP closure costs.

Β 

Net Debt

Β 

Following completion of all the transactions surrounding this change, which are expected by 30 June 2017, the impact on the Group's current net debt level will remain broadly unaffected.

Β 

Β 

Chris Smith, Chief Financial Officer of McBride, commented:

Β 

"As we prepare for the Grow phase of our strategy, we have secured an improvement in the cost, flexibility and duration of our banking facilities. The completion of this exercise represents another important milestone in the delivery of Repair, Prepare and Grow and reflects the strong ongoing support from our chosen banks."

Β 

Β 

Notes

1 - Adjusted for the impact of cross currency swap agreements.

2 - Will be treated as exceptional finance costs. Value estimated as at 23 June 2017.

3 - Will be treated as a movement on the derivative already reported in our income statement. Value estimated as at 23 June 2017.

4 - As compared to the position at 30 June 2016

Β 

Β 

For further information please contact:

Β 

McBride plc

Chris Smith, Chief Financial Officer

0161 203 7570

FTI Consulting

Ed Bridges, Nick Hasell

020 3727 1017

Β 

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation which came into effect on 3 July 2016.

Β 

-Ends-

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCFFMPTMBITBIR
Date   Source Headline
12th Jun 20267:00 amRNSTrading and Acquisition Update
11th Jun 20261:44 pmRNSDirector/PDMR Shareholding
2nd Jun 20267:00 amRNSTransaction in Own Shares
27th May 20267:00 amRNSTransaction in Own Shares
19th May 20267:00 amRNSTransaction in Own Shares
12th May 20267:00 amRNSTransaction in Own Shares
6th May 20267:00 amRNSTransaction in Own Shares
1st May 20267:00 amRNSSecond tranche of share buyback programme
1st May 20267:00 amRNSTransaction in Own Shares
29th Apr 20267:00 amRNSTransaction in Own Shares
28th Apr 20267:00 amRNSTransaction in Own Shares
21st Apr 20267:00 amRNSTransaction in Own Shares
20th Apr 20267:00 amRNSTransaction in Own Shares
16th Apr 20267:00 amRNSTransaction in Own Shares
15th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSProposed Acquisition & Trading Conditions Update
1st Apr 20267:00 amRNSTransaction in Own Shares
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 20267:00 amRNSTransaction in Own Shares
26th Mar 20267:00 amRNSTransaction in Own Shares
25th Mar 20267:00 amRNSTransaction in Own Shares
24th Mar 20267:00 amRNSTransaction in Own Shares
23rd Mar 20267:00 amRNSTransaction in Own Shares
20th Mar 20267:00 amRNSTransaction in Own Shares
19th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSDirector Appointment
10th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20266:28 pmRNSDirectorate change
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:05 amRNSInterim results for 6M ended 31 December 2025

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.